Tag

Dr Smith is a Medical Director for Europe having joined Theradex® in February 2010.

He has background training in Medical Oncology with 15 years’ clinical practice experience. He is a graduate of the Royal College of Surgeons in Ireland and completed his postgraduate training in St Bartholomew and the Royal Marsden hospital. 

Dr Smith joined the industry with PPD as Lead Medical Director for Oncology (ex-US). His responsibilities at Theradex® include evaluation of the clinical, commercial feasibility and project strategy with clients; protocol development; and selecting and liaising with clinical investigators during the clinical trial progress. He is also responsible for assessing AE and SAEs for selected European studies, commenting and preparing narrative reports for onward reporting to clients, regulatory agencies, investigators and ethics committees as necessary.

Dr Smith is also responsible for medical review of data emerging from clients’ clinical trials and for advising clients on appropriate action to be taken based on the emerging data and to advise on risk management especially risk mitigation.

Dr Smith also has experience in early access patient schemes and advising on integrating market access programs in the product lifecycle development.

Dr Smith is a member of both American Society of Clinical Oncologists and European Society of Medical Oncology.

Dr Christophe Le Tourneau is Head of the Phase I Program Institut Curie, Paris.

Euan gained a first class honours in Molecular Biology followed by a PhD in Medical Genetics from the University of Aberdeen.

In 2000 he joined Prof Hani Gabra and his team at the, then Imperial Cancer Research Fund now Cancer Research UK, unit in Edinburgh as a postdoctoral fellow.

From there he moved to Imperial College in 2003 where he ran the Molecular Therapy Lab within the Ovarian Cancer Action Research Centre. 

Since 2015 he is a Senior Investigator at GlaxoSmithKline.

Eaun is a Honorary Senior Lecturer at Imperial College London.

Dr Ioannis Pandis received a Ph.D. degree in Biological Chemistry from the BSRC “Al. Fleming” Institute in Athens, Greee in 2012.

From 2012, he has been working as a research associate at Imperial College. He is in the Discovery Science Group working on the European Innovatice Medicine Initiative (IMI), eTRIKs project, which is aimed at developing a translational information and knowledge management systems.

His personal interest is the development of bioinformatic applications enabling applied biomedical research, with a particular focus on genome regulation analysis.

Dr Jaume Reventós is the director of the Bellvitge Biomedical Research Institute (Idibell) of the University of Barcelona.

He is the co-founder of Transbiomed and was previously head of the Research Unit in Biomedicine and Translational Oncology at the Vall d’Hebron Research Institute (VHIR).

Reventós founded the VHIR spin-off Transbiomed in 2007 alongside Andreas Doll, Miguel Abal and Raimon Forés. In 2013, the company developed a test for early diagnosis of prostate cancer and began research into biomarkers for ovarian cancer.

Dr Cavallaro is a cell biologist and molecular oncologist interested in the biological mechanisms that underlie cancer development.

With his research group he discovered a novel interaction between the adhesion molecule NCAM and the receptor tyrosine kinase FGFR, introducing the paradigm that a growth factor receptor can be activated by a non-canonical ligand such as an adhesion molecule (Francavilla et al., J Cell Sci, 2007, and J Cell Biol, 2009).

His group also discovered that the NCAM/FGFR interaction plays a causal role in ovarian cancer, where it also emerged as a potential therapeutic target in preclinical models (Zecchini et al., EMBO Mol Med, 2011).

Another adhesion molecule that is intensively studied in his lab is L1, originally described as a neural adhesion molecule. They reported that L1 is expressed in specific lineages of the hematopoietic compartment, where it regulates immune cell motility and trafficking (Maddaluno et al., J Exp Med, 2009). Furthermore, his group reported that L1 plays a dual, cell context-dependent role in ovarian cancer (Zecchini et al, Cancer Res, 2008).

More recently, his research group became interested in the novel, unexpected role of adhesion molecules in tumor angiogenesis and vascular maturation. These observations led them to propose novel therapeutic target for anti-angiogenic treatments.

He is actively addressing these scientific issues in preclinical models and clinical samples of specific tumor types, such as pancreatic and ovarian carcinoma.

Another area of intense research in his group is the identification and characterisation of ovarian cancer stem cells, namely an elusive subset of transformed cells that is is thought to drive cancer development, dissemination, recurrence and chemoresistance.

Finally, they are actively pursuing the definition of novel ovarian cancer biomarkers and potential targets, combining cutting edge technologies with the use of clinically relevant specimens, taking advantage of a close collaboration with IEO gynecological oncologists

Professor Bowtell is the Head of the Cancer Genomics and Genetics Program at Peter MacCallum Cancer Centre and PI for the Australian Ovarian Cancer Study (AOCS).

Professor Bowtell is one of Australia’s leading ovarian cancer and human molecular genetics researchers.

He was Director of Research at Peter Mac for the last decade, returning to fulltime research in 2010 to lead the ovarian cancer arm of the National Health and Medical Research Council’s (NHMRC) $27 million involvement in the International Cancer Genomics Consortium, a world-wide effort aimed at mapping all the significant mutations in common cancers.

 Professor Bowtell heads the Australian Ovarian Cancer Study, a nationally collaborative project involving over 2000 women with ovarian cancer and one of the largest cohort studies of ovarian cancer in the world.

He is a molecular biologist and his lab focuses on the genomic analysis of ovarian cancer, with a focus on primary and acquired drug resistance. His lab is also funded from Cancer Australia and the US DoD to investigate high-risk BRCA mutations in women with ovarian cancer.

Professor Maria Paola Costi is a Professor of Medicinal Chemistry at the University of Modena in Italy.

In the past 15 years she has been teaching 10 different subject within Analytical Chemistry, Medicinal chemistry and Drug Design in the Faculty of Pharmacy. She also taught at the School of Doctorate in Health Science, teaching topics related to System biology approaches to drug discovery, Chemical space sorting and Medicinal chemistry in parasitology.

Professor Costi is responsible for the Laboratory of Drug Discovery of Enzyme Inhibitors of the Department of Pharmaceutical Science at University of Modena. The most of her work is focused on drug development of compounds directed to the folate pathways in different organisms, in particular in the area of anticancers and antinfectives. Another fundamental field of research is on beta-lactamase inhibitors discovery.

Recently she become involved in translational research in drug discovery in ovarian cancer. She is the co-Founder and scientific board member of the European network for translational research in ovarian cance (EUTROC).

She is also active in the technological transfer field: she is the co-Founder of the research-based biotech Tyodck Pharma, a university spin-off company and and is scientific responsible of EU projects in the area.

Professor Costi has published over 180 scientific works including papers on international journals, congress presentations, books chapters and patents. She is an external reviewer for different National and International Agencies and Scientific Journals, grant award peer reviewer.

Professor Robert Zeillinger is an Associate Professor at the Ludwig Boltzmann Institute for Gynecology and Gynecological Oncology, Department of Obstetrics and Gynecology, University of Vienna.

A graduate in biochemistry, Professor Zeillinger is also the founder and the head of the Molecular Oncology Group at The Department of Obstetrics and Gynaecology at the Medical University of Vienna. The main objectives of the group's research are understanding gynaecological cancers at molecular levels, improving diagnosis and prognosis and defining novel therapeutic targets.

The interdisciplinary group is engaged in various national and international organizations and networks (e.g. TOC – Tumor Bank Ovarian Cancer; EUTROC – European Network for Translational Research in Ovarian Cancer; OCTIPS – Ovarian Cancer Therapy Innovative Models; OVCAD – Ovarian Cancer Diagnosis; Ludwig Boltzmann Gesellschaft – Cluster Translational Oncology).

Dr. David Huntsman is a Professor in the Departments of Pathology and Laboratory Medicine and Obstetrics and Gynaecology at The University of British Columbia (UBC) and is the Dr. Chew Wei Memorial Professor of Gynaelcologic Oncology. He is a a Staff Pathologist at the BC Cancer Agency (BCCA), and a Consulting Pathologist at the Vancouver General Hospital (VGH).

Dr. Huntsman is currently the Director of the BC multidisciplinary ovarian cancer research team (OvCaRe), Medical Director of the Centre for Translational and Applied Genomics (CTAG) at the BCCA, and co-Director of the Genetic Pathology Evaluation Centre (GPEC) at the Jack Bell Research Centre, VGH.

Dr. Huntsman research has led to development of predictive and prognostic tissue based cancer biomarkers for ovarian cancer and a wide variety of other tumour types. His team created a blueprint for subtype specific ovarian cancer control and have been leaders in the application of novel genomics technologies to ovarian cancer. As collaboration is critical in his field, Dr. Huntsman happily leads and engages in a wide number of multidisciplinary research groups. Most recently he has been working on the creation of broad based personalized medicine initiative for British Columbia.

He is the leader of the TFRI sponsored program grant to study the genomes of rare cancers and to translate discoveries made into biomarkers and treatment opportunities. This team hopes to both improve the management of a cluster of rare cancers and develop strategies and ideas that will have broader clinical impact.